Conference Track

Resistance and Management of Experienced Patients

Source: CCO Independent Conference Coverage of the 2005 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Management of Treatment-Experienced Patient

Evaluation of Response to Tipranavir/Ritonavir vs Comparator Boosted PI Regimens According to Baseline Genotype
Standard Efavirenz Regimen Superior to Lopinavir/Ritonavir Plus Efavirenz as Class-Sparing Switch Strategy
Investigational Protease Inhibitor TMC114 Demonstrates Activity in Highly PI-Experienced Patients
Tipranavir/Ritonavir Superior to Lopinavir/Ritonavir in PI-Experienced HIV-Infected Patients
No Benefit from Treatment Interruption Prior to Initiation of Salvage Therapy
Treatment Interruption Prior to Salvage Therapy With Enfuvirtide Has No Effect on Virologic Response
Only Modest HIV Viral Load Increases Following Enfuvirtide Interruption in Patients With Enfuvirtide Resistance
Successful Treatment Sequencing in HIV-Infected Patients With K65R Resistance Mutation

Resistance

Expert Analysis

Resistance and Management of Experienced Patients

Program Director: John P. Phair, MD

Faculty:

Daniel R. Kuritzkes, MD
Kathleen E. Squires, MD
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data regarding the prevalence of transmitted drug resistance and rapid progression to AIDS and factors contributing to their incidence.
Discuss the efficacy and resistance issues surrounding novel treatment strategies for experienced patients, including use of newer and investigational antiretroviral agents and pre-salvage therapy treatment interruption.
Review mechanisms and rates of resistance after short-term nevirapine therapy and during continued treatment with stable failing regimens.
Describe the influence of replication capacity and drug susceptibility (and hypersusceptibility) on treatment response.

Earn CME credit by reading the expert analysis and commentary on Resistance and Management of Experienced Patients. Topics covered include:

Transmission of Multidrug-Resistant Virus and Rapid Progression
Epidemiology of Transmitted Drug Resistance
Resistance After Single-Dose Nevirapine to Prevent Transmission
Predicting Response by Susceptibility to Didanosine
Defining New Routes to Viral Hypersusceptibility
Impact of Replication Capacity on Response to Therapy
Slow Viral Evolution With a Stable Failing Regimen
Resistance During Treatment Interruption and With Enfuvirtide
Further Analyses of Tipranavir/Ritonavir in Highly Treatment-Experienced Patients
Activity of TMC114/Ritonavir in PI-Experienced Patients

CME CREDIT INFORMATION

Release Date: 04/05/05

Expiration Date: 04/04/06

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.